logo

For the Inventor, By the Inventor

Frazer, PA, United States of America

Cephalon, Inc.


USPTO Granted Patents = 248

% Expired Patents = 27.4



Trademarks = 10

Forward Citations = 2,292

Loading Chart...
Loading Chart...

279 inventors (with patents filed for the assignee):

goldMedal Robert L Hudkins (53 out of 72 patents)

silverMedal Sankar Chatterjee (41 out of 42 patents)

bronzeMedal John P Mallamo (24 out of 43 patents)

4.  Rabindranath Tripathy (19 out of 24 patents)

5.  Edward R Bacon (19 out of 64 patents)

6.  Derek D Dunn (19 out of 19 patents)

7.  Allison L Zulli (16 out of 30 patents)

8.  Michael E Lewis (16 out of 20 patents)

9.  Mohamed A Iqbal (16 out of 17 patents)

10.  Ming Tao (15 out of 24 patents)

11.  Piyush R Patel (15 out of 20 patents)

12.  Diane E Gingrich (15 out of 16 patents)

13.  Adam Clarke (14 out of 25 patents)

14.  Anthony Gerard Doyle (14 out of 32 patents)

15.  Nadine C Becknell (14 out of 20 patents)


Core Competencies:
Anti-IL-5 Antibodies
Anti-PAR-2 Antibodies
Anti-CXCR2 Antibodies
Immunoconjugates
Polynucleotides
Pharmaceutical Compositions
Bendamustine
Proteasome Inhibitors
ALK Inhibitors
JAK2 Inhibitors
Spiropiperidine Derivatives
Tricyclic Derivatives

248 patents:

1. 12577298 - Anti-IL-5 Antibodies (2026-03-17),
2. 12448392 - Spiropiperidine derivatives (2025-10-21),
3. 12441702 - Substituted 4-benzyl and 4-benzoyl piperidine derivates (2025-10-14),
4. 12410256 - Antibodies that specifically bind to TL1a and methods of treating gastrointestinal or lung diseases (2025-09-09),
5. 12410247 - Polynucleotides encoding antibodies that specifically bind to human IL-15 (2025-09-09),
6. 12384841 - Anti-PAR-2 antibodies and methods of use thereof (2025-08-12),
7. 12358980 - Compositions and methods for anti-PACAP antibodies (2025-07-15),
8. 12281148 - Anti-pd-1 antibody-attenuated IL-2 immunoconjugates and uses thereof (2025-04-21),
9. 12162946 - Antibodies that specifically bind to TL1A and methods of treating gastrointestinal disease (2024-12-10),
10. 12018084 - Anti-CXCR2 antibodies and uses thereof (2024-06-25),
11. 11725052 - Anti-PAR-2 antibodies and methods of use thereof (2023-08-15),
12. 11426706 - Cation exchange chromatography wash buffer (2022-08-30),
13. 11332534 - Anti-CXCR2 antibodies and uses thereof (2022-05-17),
14. 11267883 - Antibodies that specifically bind to human IL-15 and uses thereof (2022-03-08),
15. 11224653 - Treatment strategy for non-responders to 100MG subcutaneous mepolizumab (2022-01-18),
Company Overview
Cephalon, Inc., based in Frazer, Pennsylvania, specializes in the development and manufacturing of innovative antibody therapeutics. The company focuses on advanced treatments targeting various conditions through its expertise in anti-IL-5, anti-PAR-2, and anti-CXCR2 antibodies, as well as immunoconjugates and polynucleotides. Cephalon's commitment to pharmaceutical compositions and proteasome inhibitors positions it as a key player in the biopharmaceutical industry, dedicated to enhancing patient outcomes through cutting-edge research and development.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

Cephalon, Inc. USPTO Patent Assignee Logo
248 Patents

#1 in Frazer, PA

#70 in Pennsylvania

#1,723 in US

#3,505 in the World

Frazer, PA (US)
Frazer, PA, United States of America

Cephalon, Inc.

Forward Citations = 2,292

279 inventors:

goldMedal Robert L Hudkins (53 out of 72 patents)

silverMedal Sankar Chatterjee (41 out of 42 patents)

bronzeMedal John P Mallamo (24 out of 43 patents)

4.  Rabindranath Tripathy (19 out of 24 patents)

5.  Edward R Bacon (19 out of 64 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Cephalon, Inc.. Retrieved from https://idiyas.com/company/cephalon

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…